Lightnews — Scholar-powered news

Reposted by Carles Escriu

Dr Rachel Clarke @drrachelclarke.com · May 18

The job of a doctor is not, necessarily, to be kind or popular or fluffy or liked.

It is to do and to say the right thing for your patients.

However difficult it may be to do so.

However tough you may find it.

Many institutions pretend otherwise, including the GMC.

Here's why they're wrong 🧵

9 39 160

Carles Escriu @carlesescriu.bsky.social · Apr 28

@ajuntamentbcn.bsky.social

Brent Toderian @brenttoderian.bsky.social · Apr 27

“How Does Paris Stay Paris? By Pouring Billions Into Public Housing.”

“1/4 of residents in the French capital live in government-owned housing, part of an aggressive plan to keep lower-income Parisians— & their businesses— in the city.”

Paris innovation isn’t just about people-places & bike-lanes.

How Does Paris Stay Paris? By Pouring Billions Into Public Housing (Published 2024)

One quarter of residents in the French capital live in government-owned housing, part of an aggressive plan to keep lower-income Parisians — and their businesses — in the city.

www.nytimes.com

1 2

Carles Escriu @carlesescriu.bsky.social · Mar 8

Easy access to diagnostic investigations in primary care is likely to diagnose cancer earlier and prolong patient's lives.

Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.

NHS cancer funding needs to take the entire picture into account.

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · Mar 8

#Lungcancer is rising in young, non-smoking women. 📈

Too many face misdiagnosis & delays because it’s not expected in people their age.

Clair, Hayley, Harriet, Kizz, Becky, Stacy, Jade, & Emma were all diagnosed with stage 4 ALK+ lung cancer in their 20s, 30s, or early 40s.

#LCSM

2

Reposted by Carles Escriu

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 5

Graham Warren on smoking cessation in lung cancer pts.

Extraordinary data:

🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit

Sensational talk 🤯

7 9

Carles Escriu @carlesescriu.bsky.social · Mar 5

SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.

Translational studies to aid patient selection will now be more needed than ever.

BTOG @btog.bsky.social · Mar 5

Welcome back for the last day of #BTOG25! The first session of the day will begin at 9.00 but refreshments are available from 8am! #LCSM

Today’s Prevention and Staging session is chaired by Alan Kirk and Emma O’Dowd with Graham Warren, Richard Lee, Luigi Ventura and Helen Liddicoat speaking.

4

Reposted by Carles Escriu

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · Mar 2

New 5-year data from the CROWN trial in Asian ALK+ #lungcancer: Lorlatinib continues to show longer progression-free survival than crizotinib, with 63% progression-free at 5 years vs. 7% with crizotinib. Strong intracranial response rates too. www.jto.org/article/S155... #LCSM

First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patie...

www.jto.org

1 5

Reposted by Carles Escriu

BTOG @btog.bsky.social · Feb 18

The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...

1 2